Peptide Legal Status Tracker — 2026
Last updated June 15, 2026 · Tracking FDA 503A Category 2 reclassification
A plain-English snapshot of where popular research peptides stand with the FDA in 2026 — through the Category 2 bulk-substance list and the Pharmacy Compounding Advisory Committee (PCAC) review. We update this page as news breaks.
Peptides removed from Category 2
First PCAC hearing
Currently compoundable
Removal from Category 2 is not legalization. Each peptide still needs a PCAC recommendation and FDA rulemaking before pharmacy compounding can resume. This page is educational and not legal or medical advice.
Status by peptide
| Peptide | Next milestone |
|---|---|
BPC-157PCAC review | PCAC hearing Jul 23, 2026 |
TB-500PCAC review | PCAC hearing Jul 23, 2026 |
MOTS-cPCAC review | PCAC hearing Jul 23, 2026 |
KPVPCAC review | PCAC hearing Jul 23, 2026 |
EpitalonPCAC review | PCAC hearing Jul 24, 2026 |
SemaxPCAC review | PCAC hearing Jul 24, 2026 |
DSIP (Emideltide)PCAC review | PCAC hearing Jul 24, 2026 |
LL-37Awaiting review | Expected early 2027 |
DiHexaAwaiting review | Expected early 2027 |
PEG-MGFAwaiting review | Expected early 2027 |
Melanotan IIAwaiting review | Expected early 2027 |
GHK-Cu (injectable)Awaiting review | PCAC hearing Feb 2027 |
Get updates as the story develops
This page changes through the July PCAC hearings and into early 2027. Grab the free beginner's guide and we'll keep you posted as the FDA status shifts.
Frequently asked
Is BPC-157 legal in 2026?
BPC-157 is no longer on the FDA's Category 2 restricted list as of April 15, 2026, but it is not yet approved for pharmacy compounding. It remains available for research use only pending a PCAC review on July 23, 2026.
When could compounding pharmacies sell these peptides again?
At the earliest, late Q3 2026 — and only if the PCAC recommends approval and the FDA acts on that recommendation. Nothing is guaranteed, and each peptide is reviewed individually.
Does this affect competitive athletes?
No. WADA's prohibited list is separate from FDA compounding status. Most peptides on this page remain banned for competitive athletes regardless of any compounding changes.
What does removal from Category 2 actually mean?
It means the FDA lifted the bulk-substance safety flag that blocked these peptides from compounding review. It does not legalize them — each peptide still needs a PCAC recommendation and FDA rulemaking before pharmacy compounding can resume.